AstraZeneca has spent much of the year defending its growth prospects after disappointing drug trials and speculation about a merger that never materialized. Now the British drugmaker has a new plan to keep its ambitions on track: cut costs and put the savings toward developing its next generation of medicines.
Announced Oct. 30, the three-year restructuring program targets $1.5B in annual savings by 2029, although getting there could cost as much as $2B in one-time charges.
The savings will support AstraZeneca's drug pipeline as CEO Pascal Soriot works toward an ambitious goal of reaching $80B in annual revenue by 2030.
Cancer drugs lead growth
Oncology remains AstraZeneca's biggest strength. Cancer drug revenue rose 17% to $7.77B last quarter, supported by demand for treatments that face limited competition while their patents remain protected.
Imfinzi, an immunotherapy used to treat several cancers, brought in $2B, up 26%. Enhertu, another cancer treatment, recorded sales of $969M, while the rare disease business contributed another $2.6B.
The company's pipeline offers another reason for optimism. AstraZeneca has reported 12 positive Phase III trial results this year, the final major testing stage before a drug can seek regulatory approval.
Cancer Drugs Now Carry Nearly Half of AstraZeneca's Revenue
Q3 2026 revenue by component, $B, quarter ended Sept. 30, 2026
Pie chart. Oncology: Revenue ($B) $7.8. All other revenue: Revenue ($B) $6.8. Farxiga: Revenue ($B) $1.6.
$16.21B
- Components sum to total revenue of $16.21B.
Source: Barron's, Proactive Investors
Soriot estimates those treatments could eventually generate more than $10B in combined annual sales at their peak. Another 23 major trial results are expected in 2027, giving the company several opportunities to bring new medicines to market.
Those potential blockbusters help explain why management is willing to spend billions restructuring the business rather than simply protecting its current profits.
Patents pose a problem
The biggest challenge is replacing revenue from medicines losing their exclusivity. Farxiga, used to treat diabetes and heart conditions, saw sales fall 25% to $1.61B following the approval of its first US generic competitor in April.
Other established drugs, including Brilinta, Lynparza, and Symbicort, have already lost patent protection in some markets. More significant expirations are approaching for Calquence, Tagrisso, and Imfinzi, three treatments currently supporting growth.
Not every replacement candidate will succeed, either. Etcamah failed to meet its main goal in the SERENA-4 breast cancer trial, while Wainua disappointed in a study involving patients with a rare protein-related heart disease.
The Wainua setback added to concerns about the company's pipeline, although analysts considered the market's reaction excessive.
Competition is another concern. Pfizer, Bristol Myers Squibb, Merck, and GSK have pursued their own cost-cutting programs, leaving AstraZeneca far from alone in trying to fund growth through greater efficiency.
China could complicate expansion plans, too. Proposed restrictions on foreign acquisitions of certain biotechnology assets, alongside potential US investment limits, threaten to make cross-border deals more difficult.
Earnings offer reassurance
Despite those challenges, AstraZeneca delivered a stronger-than-expected quarter. Revenue reached $16.21B, while adjusted earnings came in at $2.79 per share, ahead of expectations.
Oncology Growth Offset the Farxiga Generics Hit
AstraZeneca Q3 2026 headline figures, quarter ended Sept. 30, 2026
| Metric | Q3 2026 | Change or comparison |
|---|---|---|
| Total revenue | $16.21B | vs $16B expected |
| Oncology revenue | $7.77B | Up 17% |
| Farxiga sales | $1.61B | Down 25% |
| Adjusted earnings per share | $2.79 | vs $2.59 expected |
Source: Barron's
Management also maintained its full-year outlook, signaling confidence that demand for its newer medicines can offset some of the pressure from generic competition.
Still, the longer-term goal is demanding. Reaching $80B in annual sales would require substantial growth from the $58.7B reported in 2025, with management counting on 20 new product launches to help close the gap.
Financial pressures haven't disappeared, either. Net debt has risen $2.5B since December to $25.8B, while the company faces a Delaware court judgment it plans to appeal.
The business continues to generate earnings to support investment, however. Nine-month core earnings per share increased 14%, giving AstraZeneca more room to fund research without relying entirely on cost reductions. Management also insists the restructuring won't mean a smaller workforce.
For investors, the question is whether AstraZeneca can develop successful new treatments quickly enough to replace the revenue it stands to lose from older medicines.
The restructuring should free up money for that effort, but the savings are only part of the equation. The upcoming clinical results will do more to determine whether AstraZeneca can deliver on its ambitious growth target.
